公开(公告)号：EP3286177A1

公开(公告)日：2018-02-28

申请号：EP16716247

申请日：2016-04-14

申请人： QURIENT CO LTD ,  LEAD DISCOVERY CENTER GMBH

发明人： NAM KIYEAN ,  KIM JAESEUNG ,  AHN SEOHYUN ,  JEON YEEJIN ,  LEE DOOHYUNG ,  PARK DONGSIK ,  YANG YOUNG-IN ,  LEE SAEYEON ,  KIM JEONGJUN ,  AHN JIYE ,  KIM HANA ,  JUNG CHUNG-WON ,  SCHULTZ-FADEMRECHT CARSTEN

IPC分类号： C07D401/14 ,  A61K31/4709 ,  A61P35/00 ,  C07D401/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

CPC分类号： C07D401/14 ,  C07D401/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

摘要： The present invention relates to novel compounds which are inhibitors of TAM (Axl, Mer and Tyro 3) and/or Met family receptor tyrosine kinases (RTKs). These compounds are suitable for the treatment of disorders associated with, accompanied by, caused by or induced by a receptor of the TAM family, in particular a hyperfunction thereof. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly immune-suppressive cancer, refractory cancer and cancer metastases.